HEALY JAMES — SEC insider filings
SEC reporting owner CIK 1245624. 70 insider filings on record with FilingPulse; latest filed 2026-10-30.
Transaction summary — filings shown
Covers the 50 most recent of 70 filings on record, filed 2022-04-14 to 2026-10-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 37 legs across 9 filings — 3,595,206 shares, $82,860,862 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 4 legs across 4 filings — 658,427 shares, $39,216,189 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 81.
- Largest priced transaction: sale of 644,000 shares @ $58.75 ($37,835,000) in Natera, Inc., filed 2023-12-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Natera, Inc. (NTRA) | Director | 20 | — | 2 legs · 646,400 sh · $37,925,498 | 22 |
| Rapport Therapeutics, Inc. (RAPP) | Director | 5 | 21 legs · 1,572,336 sh · $30,938,663 | — | 4 |
| Karuna Therapeutics, Inc. (KRTX) | Director | 8 | 7 legs · 120,047 sh · $14,742,239 | 1 leg · 6,027 sh · $1,204,771 | 18 |
| CinCor Pharma, Inc. (CINC) | Director, 10% owner | 3 | 2 legs · 506,000 sh · $15,180,000 | 1 leg · 6,000 sh · $85,920 | 5 |
| BioAge Labs, Inc. (BIOA) | Director | 3 | 5 legs · 666,665 sh · $11,999,970 | — | 5 |
| ArriVent Biopharma, Inc. (AVBP) | Director | 1 | 1 leg · 444,444 sh · $7,999,992 | — | 2 |
| Vera Therapeutics, Inc. (VERA) | 10% owner | 1 | 1 leg · 285,714 sh · $1,999,998 | — | — |
| Y-mAbs Therapeutics, Inc. (YMAB) | Director | 5 | — | — | 18 |
| Seaport Therapeutics, Inc. (SPTX) | Director | 1 | — | — | 4 |
| Bolt Biotherapeutics, Inc. (BOLT) | Director | 3 | — | — | 3 |
Insider filings — HEALY JAMES
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-30 | 4 | Rapport Therapeutics, Inc. (RAPP) | Purchase (P): 952,380 @ $21 · Purchase (P): 6,395 @ $21 · Purchase (P): 3,772 @ $21 · Purchase (P): 6,933 @ $21 | EDGAR |
| 2026-06-12 | 4 | BioAge Labs, Inc. (BIOA) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Rapport Therapeutics, Inc. (RAPP) | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Seaport Therapeutics, Inc. (SPTX) | Conversion (C): 1,927,159 · Conversion (C): 804,379 · Conversion (C): 6,052,631 (derivative) @ $0 · Conversion (C): 2,526,315 (derivative) @ $0 | EDGAR |
| 2025-09-18 | 4 | Y-mAbs Therapeutics, Inc. (YMAB) | Code (U): 31,603 @ $8.60 · Disposition to issuer (D): 25,080 · Code (U): 2,194,278 @ $8.60 · Disposition to issuer (D): 14,222 (derivative) · Disposition to issuer (D): 8,000 (derivative) · Disposition to issuer (D): 11,000 (derivative) · +5 more | EDGAR |
| 2025-07-02 | 4 | Y-mAbs Therapeutics, Inc. (YMAB) | Grant/award (A): 25,080 @ $0 · Grant/award (A): 33,450 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Rapport Therapeutics, Inc. (RAPP) | Grant/award (A): 21,850 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | BioAge Labs, Inc. (BIOA) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-04-29 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 142 | EDGAR |
| 2025-02-04 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 114 | EDGAR |
| 2024-10-29 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 153 | EDGAR |
| 2024-09-27 | 4 | BioAge Labs, Inc. (BIOA) | Conversion (C): 1,638,236 · Purchase (P): 588,888 @ $18 · Purchase (P): 11,113 @ $18 · Purchase (P): 18,353 @ $18 · Purchase (P): 21,814 @ $18 · Purchase (P): 26,497 @ $18 · +2 more | EDGAR |
| 2024-07-30 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 177 | EDGAR |
| 2024-07-03 | 4 | Rapport Therapeutics, Inc. (RAPP) | Purchase (P): 3,538 @ $23.08 · Purchase (P): 3,565 @ $24.21 · Purchase (P): 4,544 @ $25.02 · Purchase (P): 2,559 @ $26.06 · Purchase (P): 3,799 @ $23.08 · Purchase (P): 3,828 @ $24.21 · +6 more | EDGAR |
| 2024-07-02 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 2,964 | EDGAR |
| 2024-06-14 | 4 | Bolt Biotherapeutics, Inc. (BOLT) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Y-mAbs Therapeutics, Inc. (YMAB) | Grant/award (A): 3,495 @ $0 · Grant/award (A): 14,545 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Rapport Therapeutics, Inc. (RAPP) | Conversion (C): 1,392,738 @ $0 · Purchase (P): 470,589 @ $17 · Purchase (P): 18,641 @ $17 · Purchase (P): 17,861 @ $17 · Purchase (P): 26,278 @ $17 · Purchase (P): 25,455 @ $17 · +1 more | EDGAR |
| 2024-04-30 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 210 | EDGAR |
| 2024-03-18 | 4 | Karuna Therapeutics, Inc. (KRTX) | Disposition to issuer (D): 32,500 @ $330 · Disposition to issuer (D): 990 @ $330 · Disposition to issuer (D): 683 @ $330 · Disposition to issuer (D): 1,372,441 @ $330 · Disposition to issuer (D): 8,025 @ $330 · Disposition to issuer (D): 12,500 (derivative) @ $232.41 · +3 more | EDGAR |
| 2024-01-31 | 4 | ArriVent Biopharma, Inc. (AVBP) | Conversion (C): 1,252,308 · Purchase (P): 444,444 @ $18 · Conversion (C): 1,252,308 (derivative) | EDGAR |
| 2024-01-30 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 264 @ $63.79 | EDGAR |
| 2023-12-22 | 4 | Natera, Inc. (NTRA) | Sale (S): 644,000 @ $58.75 | EDGAR |
| 2023-10-31 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 396 @ $42.60 | EDGAR |
| 2023-08-01 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 328 @ $48.48 | EDGAR |
| 2023-07-05 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 2,750 · Grant/award (A): 4,255 (derivative) @ $0 | EDGAR |
| 2023-06-22 | 4 | Karuna Therapeutics, Inc. (KRTX) | Grant/award (A): 990 @ $0 · Grant/award (A): 1,904 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | Karuna Therapeutics, Inc. (KRTX) | Other (J): 400,000 @ $0 · Other (J): 8,025 @ $0 | EDGAR |
| 2023-06-14 | 4 | Bolt Biotherapeutics, Inc. (BOLT) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Y-mAbs Therapeutics, Inc. (YMAB) | Grant/award (A): 2,330 @ $0 · Grant/award (A): 13,950 (derivative) @ $0 | EDGAR |
| 2023-05-30 | 4 | Natera, Inc. (NTRA) | Option exercise (M): 3,534 · Option exercise (M): 3,534 (derivative) @ $0 | EDGAR |
| 2023-04-18 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 285 @ $54.73 | EDGAR |
| 2023-02-27 | 4 | CinCor Pharma, Inc. (CINC) jointly with Katabi Maha, Sofinnova Management X, L.P., Sofinnova Management X-A, L.L.C., Sofinnova Venture Partners X, L.P. | Sale (S): 6,000 @ $14.32 · Code (U): 9,803 · Disposition to issuer (D): 19,608 · Code (U): 6,073,949 | EDGAR |
| 2023-02-08 | 4 | Vera Therapeutics, Inc. (VERA) jointly with Sofinnova Venture Partners X, L.P., Sofinnova Management X, L.P., Katabi Maha, Sofinnova Management X-A, L.L.C. | Purchase (P): 285,714 @ $7 | EDGAR |
| 2023-01-18 | 4 | Natera, Inc. (NTRA) | Sale (S): 2,400 @ $37.71 | EDGAR |
| 2023-01-18 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 390 @ $40.01 | EDGAR |
| 2023-01-17 | 4 | Karuna Therapeutics, Inc. (KRTX) | Other (J): 300,000 @ $0 · Other (J): 6,027 @ $0 · Sale (S): 6,027 @ $199.90 | EDGAR |
| 2022-10-18 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 344 @ $45.42 | EDGAR |
| 2022-09-02 | 4/A | Natera, Inc. (NTRA) | Grant/award (A): 430 @ $0 | EDGAR |
| 2022-08-15 | 4 | CinCor Pharma, Inc. (CINC) | Purchase (P): 500,000 @ $30 · Purchase (P): 6,000 @ $30 | EDGAR |
| 2022-08-08 | 4 | CinCor Pharma, Inc. (CINC) | Option exercise (M): 29,411 @ $13.60 · Option exercise (M): 29,411 (derivative) @ $0 | EDGAR |
| 2022-08-08 | 4 | Karuna Therapeutics, Inc. (KRTX) | Option exercise (M): 32,500 @ $16 · Option exercise (M): 32,500 (derivative) @ $0 | EDGAR |
| 2022-07-19 | 4 | Y-mAbs Therapeutics, Inc. (YMAB) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2022-07-12 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 430 (derivative) @ $36.31 | EDGAR |
| 2022-07-01 | 4 | Karuna Therapeutics, Inc. (KRTX) | Purchase (P): 27,777 @ $121.99 · Purchase (P): 4,039 @ $122.95 · Purchase (P): 6,832 @ $124.73 · Purchase (P): 9,129 @ $125 · Purchase (P): 48,062 @ $122.27 · Purchase (P): 24,161 @ $123.39 | EDGAR |
| 2022-06-16 | 4 | Karuna Therapeutics, Inc. (KRTX) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Bolt Biotherapeutics, Inc. (BOLT) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2022-06-01 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 3,534 (derivative) @ $0 · Grant/award (A): 7,068 (derivative) @ $0 | EDGAR |
| 2022-05-27 | 4 | Natera, Inc. (NTRA) | Option exercise (M): 1,307 · Option exercise (M): 1,307 (derivative) @ $0 | EDGAR |
| 2022-04-14 | 4 | Karuna Therapeutics, Inc. (KRTX) | Purchase (P): 47 @ $129.38 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1245624 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs